Preprint / Version 1

Immunotherapy in TNBC

##article.authors##

  • Maha Siddiqui Polygence

DOI:

https://doi.org/10.58445/rars.1472

Keywords:

TNBC, Cancer, Immunotherapy

Abstract

This review paper focuses on the use of immunotherapy in treating Triple Negative Breast Cancer (TNBC), an aggressive breast cancer subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 protein. TNBC poses significant treatment challenges due to its lack of hormonal receptors, rendering conventional therapies like chemotherapy and radiation less effective. The review discusses the potential of immunotherapy, particularly immune checkpoint inhibitors (ICI) such as Pembrolizumab, in overcoming these challenges by activating the immune system to target and destroy cancer cells. The paper highlights ongoing clinical trials exploring combination therapies, including the use of immunotherapy with chemotherapy or radiation, aiming to enhance treatment efficacy and improve patient outcomes. It also addresses emerging research on the role of proteins like UBR5 in cancer cell evasion and the development of new treatments targeting these mechanisms. Despite the promise of immunotherapy, the review emphasizes the need for further research to understand its mechanisms, optimize treatment sequencing, and manage resistance and side effects, with the ultimate goal of achieving long-term remission and improving survival rates in TNBC patients.

References

Berger, E. R., Park, T., Saridakis, A., Golshan, M., Greenup, R. A., & Ahuja, N. (2021). Immunotherapy treatment for triple negative breast cancer. Pharmaceuticals, 14(8), 763.

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer. (2024). Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT04373031?term=NCT04373031&cond=Triple%20Negative%20Breast%20Cancer&rank=1

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation. (2024). Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05491226?term=NCT05491226&cond=Triple%20Negative%20Breast%20Cancer&rank=1

Luo, C., Wang, P., He, S., Zhu, J., Shi, Y., & Wang, J. (2022). Progress and prospect of immunotherapy for triple-negative breast cancer. Frontiers in Oncology, 12, 919072.

Wu, B., Song, M., Dong, Q., Xiang, G., Li, J., Ma, X., & Wei, F. (2022). UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer. Theranostics, 12(11), 5086–5102. https://doi.org/10.7150/thno.74989

Mandapati, A., & Lukong, K. E. (2023). Triple negative breast cancer: approved treatment options and their mechanisms of action. Journal of cancer research and clinical oncology, 149(7), 3701–3719. https://doi.org/10.1007/s00432-022-04189-6

Downloads

Posted

2024-08-18

Categories

License

Copyright (c) 2024 Maha Siddiqui

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license